These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 19486036

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
    Shimizu K, Kuroda H, Kida M, Watanabe H, Shirao S, Akiyama T, Fujimi A, Tanaka I, Sato T, Matsunaga T, Niitsu Y.
    Rinsho Ketsueki; 2005 Oct; 46(10):1152-5. PubMed ID: 16440780
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
    Kuwano Y, Asahina A, Watanabe R, Fujimoto M, Ihn H, Tamaki K.
    Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
    [No Abstract] [Full Text] [Related]

  • 8. Oral lichenoid eruption associated with imatinib treatment.
    Gómez Fernández C, Sendagorta Cudós E, Casado Verrier B, Feito Rodríguez M, Suárez Aguado J, Vidaurrázaga Díaz de Arcaya C.
    Eur J Dermatol; 2010 Oct; 20(1):127-8. PubMed ID: 19825526
    [No Abstract] [Full Text] [Related]

  • 9. Skin fragility and blistering with imatinib mesylate.
    Verma SM, Murphy G.
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):496-8. PubMed ID: 19925597
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
    Khouri S, Kotliroff A, Lishner M, Amital H.
    Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
    Vano-Galvan S, Fernandez-Guarino M, Henriquez-Santana A, De Las Heras E, Calbacho M, Jaen P.
    Eur J Dermatol; 2007 Apr; 17(6):538-9. PubMed ID: 17951138
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P.
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [Abstract] [Full Text] [Related]

  • 19. [Imatinib-induced DRESS].
    Goldman J, Duval-Modeste AB, Lambert A, Contentin N, Courville P, Musette P, Joly P.
    Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
    [Abstract] [Full Text] [Related]

  • 20. Bilateral toxoplasma retinochoroiditis in a patient with chronic myeloid leukemia treated with imatinib mesylate.
    Basu S, Das T, Biswas G.
    Ocul Immunol Inflamm; 2010 Jan; 18(1):64-5. PubMed ID: 20128654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.